請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/49591完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 李心予(Hsinyu Lee) | |
| dc.contributor.author | Yi-Cheng Weng | en |
| dc.contributor.author | 翁義程 | zh_TW |
| dc.date.accessioned | 2021-06-15T11:36:29Z | - |
| dc.date.available | 2019-08-26 | |
| dc.date.copyright | 2016-08-26 | |
| dc.date.issued | 2016 | |
| dc.date.submitted | 2016-08-16 | |
| dc.identifier.citation | Reference
[1] D.G. Zaridze, P. Boyle, M.Smans, ‘International trends in prostatic cancer’, Int J Cancer, 33 (1984), 223-230 [2] M. M. Center, A. Jemal, J. Lortet-Tieulent, E. Ward, J. Ferlay, O. Brawley, and F. Bray, 'International Variation in Prostate Cancer Incidence and Mortality Rates', Eur Urol, 61 (2012), 1079-92. [3] H. Kuruma, and S. Egawa, 'Words of Wisdom: Re: International Variation in Prostate Cancer Incidence and Mortality Rates', Eur Urol, 63 (2013), 583-4. [4] P. Saraon, K. Jarvi, and E. P. Diamandis, 'Molecular Alterations During Progression of Prostate Cancer to Androgen Independence', Clin Chem, 57 (2011), 1366-75. [5] G. Attard, D. Sarker, A. Reid, R. Molife, C. Parker, and J. S. de Bono, 'Improving the Outcome of Patients with Castration-Resistant Prostate Cancer through Rational Drug Development', Br J Cancer, 95 (2006), 767-74. [6] B. Mellado, M. Marin Aguilera, M.V. Pereira, 'Molecular biology of castrate-resistant prostate cancer: Basis for the novel therapeutic targets', Arch Esp Urol, 66 (2013), 453-462 [7] Y. C. Lu, W. C. Weng, and H. Lee, 'Functional Roles of Calreticulin in Cancer Biology', Biomed Res Int, 2015 (2015), 526524. [8] M. Zamanian, A. Veerakumarasivam, S. Abdullah, and R. Rosli, 'Calreticulin and Cancer', Pathol Oncol Res, 19 (2013), 149-54. [9] T. Pozzan, R. Rizzuto, P. Volpe, and J. Meldolesi, 'Molecular and Cellular Physiology of Intracellular Calcium Stores', Physiol Rev., 74 (1994), 595-636. [10] Jacopo Meldolesi, and Tullio Pozzan, 'The Endoplasmic Reticulum Ca 2+ Store: A View from the Lumen', Trends Biochem Sci, 23 (1998), 10-14. [11] M. Villagomez, E. Szabo, A. Podcheko, T. Feng, S. Papp, and M. Opas, 'Calreticulin and focal-contact-dependent adhesion', Biochem Cell Biol, 87 (2009), 545-556 [12] Marc P. Fadel, Ewa Dziak, Chun-Min Lo, Jack Ferrier, Nasrin Mesaeli, Marek Michalak, and Michal Opas, 'Calreticulin Affects Focal Contact-Dependent but Not Close Contact-Dependent Cell-Substratum Adhesion', J Biol Chem, 274 (1999), 15084-94. [13] S. Papp, E. Szabo, H. Kim, C. A. McCulloch, and M. Opas, 'Kinase-Dependent Adhesion to Fibronectin: Regulation by Calreticulin', Exp Cell Res, 314 (2008), 1313-26. [14] S. Papp, M. P. Fadel, H. Kim, C. A. McCulloch, and M. Opas, 'Calreticulin Affects Fibronectin-Based Cell-Substratum Adhesion Via the Regulation of C-Src Activity', J Biol Chem, 282 (2007), 16585-98. [15] H. Totary-Jain, T. Naveh-Many, Y. Riahi, N. Kaiser, J. Eckel, and S. Sasson, 'Calreticulin Destabilizes Glucose Transporter-1 Mrna in Vascular Endothelial and Smooth Muscle Cells under High-Glucose Conditions', Circ Res, 97 (2005), 1001-8. [16] T. K. White, Q. Zhu, and M. L. Tanzer, 'Cell surface calreticulin is a putative mannoside lectin which triggers mouse melanoma cell spreading', J Biol Chem, 270 (1995), 15926-15929 [17] P. Ramsamooj, V. Notario, and A. Dritschilo, 'Enhanced Expression of Calreticulin in the Nucleus of Radioresistant Squamous Carcinoma Cells in Response to Ionizing Radiation', Cancer Res., 55 (1995), 3016-21. [18] C. Labriola, J. J. Cazzulo, and A. J. Parodi, 'Trypanosoma Cruzi Calreticulin Is a Lectin That Binds Monoglucosylated Oligosaccharides but Not Protein Moieties of Glycoproteins', Mol Biol Cell, 10 (1999), 1381-94. [19] A. Zapun, N. J. Darbyi, D. C. Tessier, M. Michalak, J. J. M. Bergeron, and D. Y. Thomas, 'Enhanced Catalysis of Ribonuclease B Folding by the Interaction of Calnexin or Calreticulin with Erp57*', J Biol Chem, 273 (1998), 6009-12. [20] A. Vassilakos, M. Michalak, M. A. Lehrman, and D. B. Williams, 'Oligosaccharide Binding Characteristics of the Molecular Chaperones Calnexin and Calreticulin', Biochemistry-Us, 37 (1998), 3480-90. [21] G. Nickenig, F. Michaelsen, C. Muller, A. Berger, T. Vogel, A. Sachinidis, H. Vetter, and M. Bohm, 'Destabilization of At1 Receptor Mrna by Calreticulin', Circ Res, 90 (2002), 53-58. [22] C. N. Chen, C. C. Chang, T. E. Su, W. M. Hsu, Y. M. Jeng, M. C. Ho, F. J. Hsieh, P. H. Lee, M. L. Kuo, H. Lee, and K. J. Chang, 'Identification of Calreticulin as a Prognosis Marker and Angiogenic Regulator in Human Gastric Cancer', Ann Surg Oncol, 16 (2009), 524-33. [23] Z. M. Lwin, C. Guo, A. Salim, G. W. Yip, F. T. Chew, J. Nan, A. A. Thike, P. H. Tan, and B. H. Bay, 'Clinicopathological Significance of Calreticulin in Breast Invasive Ductal Carcinoma', Mod Pathol, 23 (2010), 1559-66. [24] O. Vaksman, B. Davidson, C. Trope, and R. Reich, 'Calreticulin Expression Is Reduced in High-Grade Ovarian Serous Carcinoma Effusions Compared with Primary Tumors and Solid Metastases', Hum Pathol, 44 (2013), 2677-83. [25] W. F. Chiang, T. Z. Hwang, T. C. Hour, L. H. Wang, C. C. Chiu, H. R. Chen, Y. J. Wu, C. C. Wang, L. F. Wang, C. Y. Chien, J. H. Chen, C. T. Hsu, and J. Y. Chen, 'Calreticulin, an Endoplasmic Reticulum-Resident Protein, Is Highly Expressed and Essential for Cell Proliferation and Migration in Oral Squamous Cell Carcinoma', Oral Oncol, 49 (2013), 534-41. [26] E. Miyoshi, K. Moriwaki, and T. Nakagawa, 'Biological Function of Fucosylation in Cancer Biology', J Biochem, 143 (2008), 725-9. [27] A. G. Turner, 'Haptoglobin. A potential reporter molecule for glycosylation changes in disease', Adv Exp Med Biol, 376 (1995), 725-29 [28] E. Mas, E. Pasqualini, N. Caillol, A. E. Battari, C. Crotte, D. Lombardo, and M. Sadoulet, 'Fucosyltransferase Activities in Human Pancreatic Tissue: Comparative Study between Cancer Tissues and Established Tumoral Cell Lines', Glycobiology, 8 (1998), 605-13. [29] H. Baumann, E. Nudelman, K. Watanabe, and S. Hakomori, 'Neutral Fucolipids and Fucogangliosides of Rat Hepatoma Htc and H35 Cells, Rat Liver, and Hepatocytes', Cancer Res, 39 (1979), 2637-43. [30] Yasuhiro Ito, Akira Miyauchi, Hiroshi Yoshida, Takashi Uruno, Keiichi Nakano, Yuuki Takamura, Akihiro Miya, Kaoru Kobayashi, Tamotsu Yokozawa, Fumio Matsuzuka, Naoyuki Taniguchi, Nariaki Matsuura, Kanji Kuma, and Eiji Miyoshi, 'Expression of Α1,6-Fucosyltransferase (Fut8) in Papillary Carcinoma of the Thyroid: Its Linkage to Biological Aggressiveness and Anaplastic Transformation', Cancer Letters, 200 (2003), 167-72. [31] J. K. Jin, P. C. Tien, C. J. Cheng, J. H. Song, C. Huang, S. H. Lin, and G. E. Gallick, 'Talin1 Phosphorylation Activates Beta1 Integrins: A Novel Mechanism to Promote Prostate Cancer Bone Metastasis', Oncogene, 34 (2015), 1811-21. [32] Y. C. Lu, C. N. Chen, C. Y. Chu, J. Lu, B. J. Wang, C. H. Chen, M. C. Huang, T. H. Lin, C. C. Pan, S. S. Chen, W. M. Hsu, Y. F. Liao, P. Y. Wu, H. Y. Hsia, C. C. Chang, and H. Lee, 'Calreticulin Activates Beta1 Integrin Via Fucosylation by Fucosyltransferase 1 in J82 Human Bladder Cancer Cells', Biochem J, 460 (2014), 69-78. [33] D. A. Cheresh, 'Structural and biologic properties of integrin-mediated cell adhesion', Clin Lab Med, 12 (1992), 217-36 [34] M. Amin Arnaout, Simon Goodman, and Jian-Ping Xiong, 'Structure and Mechanics of Integrin-Based Cell Adhesion', Curr Opin Cell Biol, 19 (2007), 495-507. [35] Sen-itiroh Hakomori, 'Tumor Malignancy Defined by Aberrant Glycosylation and Sphingo(Glyco)Lipid Metabolism', Cancer Res, 56 (1996), 5309-18. [36] Paweł Link-Lenczowski, and Anna Lityńska, 'Glycans in melanoma screening. Part 2. Towards the understanding of integrin N-glycosylation in melanoma', Biochem Soc Trans, 39 (2011), 374-77 [37] James W. Dennis, Maria Granovsky, and Charles E.Warren, 'Protein Glycosylation in Development and Disease', Bioessays, 21 (1999), 412-21. [38] S. J. Shattil, C. Kim, and M. H. Ginsberg, 'The Final Steps of Integrin Activation: The End Game', Nat Rev Mol Cell Biol, 11 (2010), 288-300. [39] K. Vougas, E. Gaitanarou, E. Marinos, C. Kittas, Voloudakis-Baltatzis IE, 'Two-dimensional electrophoresis and immunohistochemical study of calreticulin in colorectal adenocarcinoma and mirror biopsies', J Blacan Union Oncol, 13 (2008), 101–107 [40] A. Eric, Z. Juranic, Z. Milovanovic, I. Markovic, M. Inic, N. Stanojevic-Bakic, and V. Vojinovic-Golubovic, 'Effects of Humoral Immunity and Calreticulin Overexpression on Postoperative Course in Breast Cancer', Pathol Oncol Res, 15 (2009), 89-90. [41] S. Kageyama, T. Isono, H. Iwaki, Y. Wakabayashi, Y. Okada, K. Kontani, K. Yoshimura, A. Terai, Y. Arai, and T. Yoshiki, 'Identification by Proteomic Analysis of Calreticulin as a Marker for Bladder Cancer and Evaluation of the Diagnostic Accuracy of Its Detection in Urine', Clin Chem, 50 (2004), 857-66. [42] K. Hellman, A. A. Alaiya, K. Schedvins, W. Steinberg, A. C. Hellstrom, and G. Auer, 'Protein Expression Patterns in Primary Carcinoma of the Vagina', Br J Cancer, 91 (2004), 319-26. [43] W. M. Hsu, F. J. Hsieh, Y. M. Jeng, M. L. Kuo, C. N. Chen, D. M. Lai, L. J. Hsieh, B. T. Wang, P. N. Tsao, H. Lee, M. T. Lin, H. S. Lai, and W. J. Chen, 'Calreticulin Expression in Neuroblastoma--a Novel Independent Prognostic Factor', Ann Oncol, 16 (2005), 314-21. [44] Ayodele Alaiya, Uwe Roblick, Lars Egevad, Adelaide Carlsson, Bo Franzen, Daniela Volz, Soren Huwendiek, Stig Linder, and and Gert Auer, 'Polypeptide Expression in Prostate Hyperplasia and Prostate Adenocarcinoma', Analytical Cellular Pathology, 21 (2000), 1-9. [45] M. Alur, M. M. Nguyen, S. E. Eggener, F. Jiang, S. S. Dadras, J. Stern, S. Kimm, K. Roehl, J. Kozlowski, M. Pins, M. Michalak, R. Dhir, and Z. Wang, 'Suppressive Roles of Calreticulin in Prostate Cancer Growth and Metastasis', Am J Pathol, 175 (2009), 882-90. [46] Y. C. Lu, C. N. Chen, B. Wang, W. M. Hsu, S. T. Chen, K. J. Chang, C. C. Chang, and H. Lee, 'Changes in Tumor Growth and Metastatic Capacities of J82 Human Bladder Cancer Cells Suppressed by Down-Regulation of Calreticulin Expression', Am J Pathol, 179 (2011), 1425-33. [47] E. Maverakis, K. Kim, M. Shimoda, M. E. Gershwin, F. Patel, R. Wilken, S. Raychaudhuri, L. R. Ruhaak, and C. B. Lebrilla, 'Glycans in the Immune System and the Altered Glycan Theory of Autoimmunity: A Critical Review', J Autoimmun, 57 (2015), 1-13. [48] T. Koike, N. Kimura, K. Miyazaki, T. Yabuta, K. Kumamoto, S. Takenoshita, J. Chen, M. Kobayashi, M. Hosokawa, A. Taniguchi, T. Kojima, N. Ishida, M. Kawakita, H. Yamamoto, H. Takematsu, A. Suzuki, Y. Kozutsumi, and R. Kannagi, 'Hypoxia Induces Adhesion Molecules on Cancer Cells: A Missing Link between Warburg Effect and Induction of Selectin-Ligand Carbohydrates', Proc Natl Acad Sci U S A, 101 (2004), 8132-7. [49] S. Bassaganas, S. Carvalho, A. M. Dias, M. Perez-Garay, M. R. Ortiz, J. Figueras, C. A. Reis, S. S. Pinho, and R. Peracaula, 'Pancreatic Cancer Cell Glycosylation Regulates Cell Adhesion and Invasion through the Modulation of Alpha2beta1 Integrin and E-Cadherin Function', PLoS One, 9 (2014), e98595. [50] Ching-Long Chen, Chang-Min Liang, Yi-Hao Chen, Ming-Cheng Tai, Da-Wen Lu, and Jiann-Torng Chen, 'Glucosamine Modulates Tnf-a–Induced Icam-1 Expression and Function through O-Linked and N-Linked Glycosylation in Human Retinal Pigment Epithelial Cells', Invest Ophthalmol Vis Sci, 53 (2012), 2281-91. [51] Z. Zhang, P. Sun, J. Liu, L. Fu, J. Yan, Y. Liu, L. Yu, X. Wang, and Q. Yan, 'Suppression of Fut1/Fut4 Expression by Sirna Inhibits Tumor Growth', Biochim Biophys Acta, 1783 (2008), 287-96. [52] J. Gu, T. Isaji, Q. Xu, Y. Kariya, W. Gu, T. Fukuda, and Y. Du, 'Potential Roles of N-Glycosylation in Cell Adhesion', Glycoconj J, 29 (2012), 599-607. [53] N. D. Rambaruth, and M. V. Dwek, 'Cell Surface Glycan-Lectin Interactions in Tumor Metastasis', Acta Histochem, 113 (2011), 591-600. [54] Y. Zhao, S. Itoh, X. Wang, T. Isaji, E. Miyoshi, Y. Kariya, K. Miyazaki, N. Kawasaki, N. Taniguchi, and J. Gu, 'Deletion of Core Fucosylation on Alpha3beta1 Integrin Down-Regulates Its Functions', J Biol Chem, 281 (2006), 38343-50. [55] J. Jokinen, E. Dadu, P. Nykvist, J. Kapyla, D. J. White, J. Ivaska, P. Vehvilainen, H. Reunanen, H. Larjava, L. Hakkinen, and J. Heino, 'Integrin-Mediated Cell Adhesion to Type I Collagen Fibrils', J Biol Chem, 279 (2004), 31956-63. [56] Stephanie M. Jung, and Masaaki Moroi, 'Activation of the Platelet Collagen Receptor Integrin A2b1', TCM, 10 (2000), 285-92. [57] William D. Staatz, John J. Walsh, Terry Pexton, and Samuel A. Santoro, 'The Cx& Integrin Cell Surface Collagen Receptor Binds to the Al(I)-Cb3 Peptide of Collagen', J Biochem, 265 (1989), 4778-81. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/49591 | - |
| dc.description.abstract | 鈣網蛋白是一種主要分佈在內質網當中的伴護蛋白，已知會影響膀胱癌細胞的生長與移行。在過去研究中，我們發現鈣網蛋白會增加膀胱癌細胞內岩藻醣轉移酶的表現，並且提升β1型整合蛋白的岩藻醣化與細胞的貼附能力。然而，鈣網蛋白在前列腺癌細胞當中對於上述細胞生理機制的影響仍未明確，因此在本研究中，我們將研究鈣網蛋白在前列腺癌細胞中所扮演的角色。實驗結果顯示，在抑制鈣網蛋白表現後，岩藻醣轉移酶表現量與β1型整合蛋白之岩藻醣化程度下降，且岩藻醣轉移酶轉移酶表現量的的影響可能是透過可能是透過調節其mRNA穩定性。此外，抑制鈣網蛋白表現亦會降低細胞的貼附能力與整合蛋白的活化程度。這些結果表示鈣網蛋白對於前列腺癌細胞的移行可能有重要影響，並且可能是透過岩藻醣轉移酶來達成，未來對鈣網蛋白的更深入研究將有助於前列腺癌治療的發展。 | zh_TW |
| dc.description.abstract | Calreticulin (CRT) is a multifunctional ER chaperon protein and it had been revealed that knockdown of CRT may suppress cell proliferation and migration in J82 bladder cancer cell. We had further demonstrated that CRT enhanced the expression of fucosyltransferase1 (FUT1), which leads to an enhancement of fucosylation of beta1 integrin, and promote cell adhesion in J82 cells. Previous studies had shown that knockdown of CRT suppress cell proliferation and migration in PC3 prostate cancer cell as well. However, the effects by CRT on integrin fucosylation have not been revealed in prostate cancer so far. In this study, therefore, we attempted to investigate whether CRT affect FUT1 expression and integrin fucosylation in PC3 prostate cancer cells as well. Our results showed that FUT1 expression and beta1 integrin fucosylation are suppressed after knockdown of CRT. Futhermore, cell adhesion and integrin activation are down regulated as well. These observations imply that CRT might regulate prostate cancer metastasis through FUT1 and therefore could be a potential target for development of cancer treatments. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-15T11:36:29Z (GMT). No. of bitstreams: 1 ntu-105-R03b21009-1.pdf: 1086674 bytes, checksum: efefc677f65413638d57d5c217e13367 (MD5) Previous issue date: 2016 | en |
| dc.description.tableofcontents | Contents
致謝-----------------------------------------------------------------------------------------------3 中文摘要-----------------------------------------------------------------------------------------4 Abstract-------------------------------------------------------------------------------------------5 Introduction-------------------------------------------------------------------------------------6 Prostate cancer------------------------------------------------------------------------------6 Calreticulin and its role in cancer--------------------------------------------------------7 Fucosylation and its role in cancer-------------------------------------------------------9 Functional roles of integrin family and integrin activation-------------------------10 Rationale----------------------------------------------------------------------------------------12 Materials and Methods---------------------------------------------------------------------- 13 Generation of CRT-RNAi cells and cell culture-------------------------------------13 RNA extraction and real-time PCR----------------------------------------------------13 Western blotting--------------------------------------------------------------------------15 UEA1 lectin pull down assay-----------------------------------------------------------16 Cell adhesion assay-----------------------------------------------------------------------16 Determination of integrin activation---------------------------------------------------17 Determination of mRNA stability------------------------------------------------------17 In situ digestion---------------------------------------------------------------------------17 Purification of fucosylated peptides----------------------------------------------------18 LC-MS/MS analysis----------------------------------------------------------------------18 Statistical analysis------------------------------------------------------------------------19 Results-------------------------------------------------------------------------------------------20 Generation of stable CRT-knockdown cell lines-------------------------------------20 Calreticulin regulates FUT1 expression in mRNA and protein levels------------20 Beta1 integrin fucosylation was suppressed in CRT-KD cell lines----------------21 Cell adhesion was regulated by calreticulin and fucosylated membrane protein--------------------------------------------------------------------------------------21 Exposure of HUTS-21 epitopes were reduced after knockdown of CRT ----------------------------------------------------------------------------------------------22 Discussion---------------------------------------------------------------------------------------24 Reference----------------------------------------------------------------------------------------28 Figures-------------------------------------------------------------------------------------------34 Supplemental Figures and Table-----------------------------------------------------------45 | |
| dc.language.iso | en | |
| dc.title | 鈣網蛋白在前列腺癌細胞中調控岩藻醣轉移酶表現及β1型整合蛋白岩藻醣化之研究 | zh_TW |
| dc.title | Calreticulin regulates FUT1 expression and beta1 integrin fucosylation in PC3 prostate cancer cells | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 104-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 黃元勵,蔡有光,朱家瑩 | |
| dc.subject.keyword | 前列腺癌,鈣網蛋白,岩藻醣化,β1型整合蛋白, | zh_TW |
| dc.subject.keyword | Prostate cancer,Calreticulin,Fucosylation,Beta1 integrin, | en |
| dc.relation.page | 49 | |
| dc.identifier.doi | 10.6342/NTU201602645 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2016-08-16 | |
| dc.contributor.author-college | 生命科學院 | zh_TW |
| dc.contributor.author-dept | 生命科學系 | zh_TW |
| 顯示於系所單位： | 生命科學系 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-105-1.pdf 目前未授權公開取用 | 1.06 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。